Bee Vectoring Technologies International Inc. (the "Company" or "BVT") recently announced the European Patent Office (EPO) has granted Patent Application No. 2693871 entitled: Apparatus for Treatment of Plants.

With the grant by the EPO the Company can now validate the patent in the 38 countries that are Member States of the European Patent Organisation. This is a procedural step, which includes filing some paperwork and paying a validation fee, but no further review is required. The Company will validate the patent in countries based on the size of the market opportunity that exists in each country.
 
BVT CEO Ashish Malik said, "Europe as a region represents a significant revenue opportunity for the Company. The market forces driving growers to adopt sustainable crop production practices are significant across Europe. They favor the reduction in use of chemicals and adoption of practices that reduce the impact of agriculture on the environment have been faster in Europe than in other regions. This is what BVT's system is all about." Malik added, "This is our first patent approved by the EPO; 3 other patents are currently under review. As we develop our system for growers across Europe and advance our business development discussions with potential partners, this patent and the others that will follow, will allow us to assert our intellectual property rights and give us a competitive advantage."
 
BVT's technology described in the patent includes a specialist apparatus for the treatment of plants with inoculants and control agents to manage diverse diseases and pests and enhance the yield and quality of crops. The inoculants and control agents are housed in proprietary removable trays within a dispenser system that is incorporated in the lid of commercial bumble bee hives. The bumble bees pick up the product on their way out of the hive and deliver the treatment to the plant in a very targeted and sustainable way. BVT has also filed a patent application with the US patent office for a unique and novel system that allows the delivery of plant protection products to crops using commercial honeybees.
 
The Company is pursuing an aggressive Intellectual Property (IP) strategy that covers five different patent families and 60 patent applications worldwide. The IP strategy supports the Company's documented growth strategy to selectively expand its market opportunities while it continues down the path towards securing US Environmental Protection Agency (EPA) regulatory approval of its BVT-CR7 beneficial microbe and drives towards commercialization of its proprietary system.